methyl 2-(-5-fluoro-2-hydroxyphenyl)-1 H-benzo(d)imidazole-5-carboxylate

05/30/2021 - "Pyridocarbazoles 9 was also moderately effective against all the employed cancer cell lines and moreover showed excellent biofilm inhibition (9a: MBIC = 100 µM; 9b: MBIC = 100 µM)."
03/01/2024 - "Mithilfe von Datensätzen aus 2 Instituten und dem öffentlich zugänglichen TCGA-MBIC-Datensatz (TCGA, The Cancer Genome Atlas) wurden Convolutional Neural Networks (CNN) und Vision Transformer (ViT) für Vorhersagen an Urothelgewebe (Karzinom- vs. Normalgewebe) und an intrahepatischen Cholangiokarzinomen (iCCA, „small vs. large duct“) trainiert. "
10/01/2020 - "Furthermore, another known compound, 1,3,6-trihydroxy-7-methoxy-9H-xanthen-9-one, was obtained in smaller amounts and revealed a non-microbicidal 100 % reduction in biofilm formation, with an MBIC value of 62.5 μg/mL (228 μM) against Pseudomonas aeruginosa (Ferm-BAM), a FRAP value of 447.941±37.876 mM/L as well as a marked safety profile against three cancer cell lines. "
04/25/2017 - "In addition, 4 weeks of MBIC administration in MDA-MB-231 cells inoculated BALB/c nude mice resulted in 79.7% reduction of tumor volume compared to the untreated group with no severe sign of toxicity. "
02/21/2017 - "Finally, MBIC significantly inhibited tumor growth at a dose of 25 mg/kg in an orthotopic HCC mouse model. "

04/25/2017 - "In this study, we demonstrated that MBIC exhibits greater toxicity towards non-aggressive breast cancer cell-line, MCF-7 (IC50 = 0.73 ± 0.0 μM) compared to normal fibroblast cell-line, L-cells (IC50 = 59.6 ± 2.5 μM). "
01/01/2018 - "The present findings suggest that inhibition of autophagy eliminates the cytoprotective activity of MDA-MB-231 and MCF-7 cells, and sensitizes both the aggressive and non-aggressive human breast cancer cell-lines to the cytotoxic effects of MBIC."
01/01/2018 - "The cytotoxic effect of MBIC was enhanced by inhibition of autophagy through blockage of SAPK/JNK signaling, suggesting that MBIC-induced autophagy, is a possible cellular self-defense mechanism against toxicity of this agent in both breast cancer cell-lines. "
01/01/2018 - "Activation of autophagy by stress-activated signals as a cellular self-defense mechanism against the cytotoxic effects of MBIC in human breast cancer cells in vitro."
04/25/2017 - "The IC50 of MBIC against the aggressive breast cancer cell-line, MDA-MB-231 was 20.4 ± 0.2 μM. "

01/01/2019 - "Different biofilm susceptibility endpoint parameters like the minimal biofilm eradication concentration (MBEC) or the minimal biofilm inhibitory concentration (MBIC) have been suggested as a guide for treatment of biofilm-associated infections, however with inconsistent perception and use among biofilm researchers, leading to confusion and contradictions among different anti-biofilm component studies and clinical trials. "
01/02/2023 - "Here, the potential expressed by the recently discovered peptide Dadapin-1 was explored by assaying its MIC, MBIC and MBC on clinical strains of relevant bacterial species isolated from orthopedic infections and by assessing its cytotoxicity on the human osteoblast-like MG63 cells. "
08/30/2022 - "Time kill analyses (TKA) were performed against R497 and HOU503 with DAP at 0.5× MBIC, ampicillin (AMP) at free peak = 72 µg/mL, and phage at a multiplicity of infection (MOI) of 0.01. "

02/21/2017 - "In the present study, we found that MBIC inhibited cell viability in different hepatocellular carcinoma (HCC) cell lines without exerting significant cytotoxic effects on normal liver cells. "
02/21/2017 - "A novel benzimidazole derivative, MBIC inhibits tumor growth and promotes apoptosis via activation of ROS-dependent JNK signaling pathway in hepatocellular carcinoma."

01/01/2019 - "Different biofilm susceptibility endpoint parameters like the minimal biofilm eradication concentration (MBEC) or the minimal biofilm inhibitory concentration (MBIC) have been suggested as a guide for treatment of biofilm-associated infections, however with inconsistent perception and use among biofilm researchers, leading to confusion and contradictions among different anti-biofilm component studies and clinical trials. "